FindTrial
Sign In

Etripamil

DRUG6 trials

Sponsors

Milestone Pharmaceuticals Inc.

Conditions

Atrial FibrillationParoxysmal Supraventricular TachycardiaParoxysmal Supraventricular Tachycardia (PSVT)Paroxysmal supraventricular tachycardia (PSVT)

Phase 2

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
CompletedNCT02296190
Milestone Pharmaceuticals Inc.Paroxysmal Supraventricular Tachycardia (PSVT)
Start: 2015-03-27End: 2016-12-31Updated: 2020-12-30
ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
CompletedNCT04467905
Milestone Pharmaceuticals Inc.Atrial Fibrillation
Start: 2020-11-19End: 2023-08-10Updated: 2024-09-19
The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients with Paroxysmal Supraventricular Tachycardia
RecruitingCTIS2022-500319-38-00
Milestone Pharmaceuticals Inc.Paroxysmal supraventricular tachycardia (PSVT)
Start: 2024-05-03Target: 30Updated: 2025-08-29

Phase 3

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
TerminatedNCT03464019
Milestone Pharmaceuticals Inc.Paroxysmal Supraventricular Tachycardia
Start: 2018-06-18End: 2023-01-20Updated: 2024-07-12
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
RecruitingNCT06716021
Milestone Pharmaceuticals Inc.Atrial Fibrillation
Start: 2026-08-20End: 2029-12-01Target: 750Updated: 2026-09-09
Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.
Not yet recruitingCTIS2024-516251-40-01
Milestone Pharmaceuticals Inc.Atrial Fibrillation
Target: 200Updated: 2026-07-27

Related Papers

Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)
Circulation Arrhythmia and Electrophysiology2023-11-1110 citations
Podcast on Self-administered Intranasal Etripamil for Symptomatic Paroxysmal Supraventricular Tachycardia: The RAPID Trial.
2023-11-10
Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study
Journal of the American Heart Association2023-09-2710 citations
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.
2023-06-1519 citations
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)
Circulation Arrhythmia and Electrophysiology2022-11-2839 citations
Abstract 9925: Patient-Reported Treatment Satisfaction in Etripamil-Mediated Conversion of Supraventricular Tachycardia to Sinus Rhythm: Results From the NODE-301 Study
Circulation2022-11-08
Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia
American Heart Journal2022-06-188 citations
Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm
Journal of the American College of Cardiology2018-07-0168 citations